Granon (Acetylcysteine)

Granon is commonly used for chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma with mucus hypersecretion, cystic fibrosis as an adjunct, and acute respiratory infections where mucus clearance is needed.

The regulatory status of Granon varies by country; in the European Union its prescription or OTC status is not definitively specified.

Safety data for Granon during pregnancy or lactation are limited; healthcare providers should evaluate the risk‑benefit profile before prescribing to these populations.

Common adverse effects include nausea, vomiting, diarrhea, abdominal discomfort, and a metallic taste in the mouth.

Serious reactions, although rare, may include allergic rash, urticaria, anaphylaxis, severe bronchospasm, and significant elevations in liver enzymes.

Patients with renal impairment should be monitored closely, as acetylcysteine is cleared renally and dose adjustment may be required.

There are no specific dietary restrictions, but taking Granon with food may reduce gastrointestinal upset in some individuals.

Activated charcoal can bind acetylcysteine and reduce its absorption; therefore, concurrent use should be avoided.

Concurrent use is possible, but caution is advised because additive bronchospasm may occur in susceptible patients.

Regular assessment of liver function, renal function, and evaluation for any allergic reactions or gastrointestinal symptoms is recommended during prolonged treatment.

Acetylcysteine, the active ingredient in Granon, is used as an adjunct to standard cystic fibrosis therapy to help thin mucus, but it is not a primary disease‑modifying treatment.